|
|
Profile
|
Delegates :
Dr. Tadashi Matsumoto |
|
Incorporated :
May 12 , 1998 |
Paid in Capital :
742 Million yen |
Employees :
11 人 |
Address :
Mitsui-Life Bldg. 1-7-23 Morino, Machida-City TOKYO
〒194-0022
|
TEL/FAX :
+81-42-732-2207 / +81-42-732-2208 |
URL：
http://www.reqmed.co.jp/ |
Attachment :
|
Mission/Background :
ReqMed Company is a privately-held biopharma company, headquartered in Tokyo, Japan. The company name “ReqMed” is derived from our corporate mission, to provide "Required Medicine for all who request it". Since ReqMed was established in May 1998, ReqMed has been dedicated to bio and pharmaceutical industry as BioBiz Navigator. ReqMed is engaged in drug development and business consulting. |
|
Technology & Business
|
ReqMed is focusing on the therapeutic areas with unmet medical needs, and we have our clinical-stage pipelines for Homocystinuria, Tropical Spastic Paraparesis (TSP), Osteoarthritis, and CNS diseases, such as ADHD, Schizophrenia and Parkinson's disease. Taking the collaboration with academia and our partner companies, and grants by the government and patient groups, ReqMed aims to conduct efficient and cost-effective development.
Meanwhile, as our business consulting services, ReqMed supports a variety of clients worldwide, such as pharmaceuticals, biotechs, diagnostics, medical device companies, CROs and CMOs in their business development, licensing and partnering activities.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Sodium Pentosan Polysulfate
|
Phase2
|
Osteoarthritis (OA), Tropical Spastic Paraparesis (TSP) / HTLV-1 associated myelopathy (HAM)
|
Finding development and marketing partner
|
Eltoprazine
|
Phase2
|
ADHD, Cognitive Impairment Associated with Schizophrenia, Dyskinesia in Parkinson's disease
|
Finding development and marketing partner
|
Betaine
|
NDA filed
|
Homocystinuria, Pharmaceutical Development Support program
|
Approved in Japan by the end of 4Q in 2013
|
|
|
|
|
|
|
|
|
|
Highlights
|
- NDA for Betaine was filed in Jpana at the end of March in 2013.
- A POC study of Eltoprazine for Cognitive Impairment in Schizophrenia as the TUNRS program supported by US-NIH was completed.
|
|
Hot news
|
At Alliance Promotion, we would like to introduce recent significant progress in Pentosan research and current situation of Pentosan program for the treatment of Tropical Spastic Paraparesis (TSP) / HTLV-1 associated myelopathy (HAM). In addition, we will introduce Betain, for which we filed a new drug application with the PMDA in March, and our other therapeutic programs.
|
|
Alliance strategy
|
- Drug development projects: We are seeking a co-development and marketing partner of Eltoprazine and Pentosan in Japan, Korea (for eltoprazine), China and Taiwan.
- Business consulting: We introduce a variety of clients' partnering opportunities, including licensing programs, drug discovery platforms, CMO services and preclinical CRO services. We also support our clients in their business development and licensing activities based on our expertise and global network in the pharma and biotech industries.
|
|
|